81171-71-3Relevant articles and documents
Synthetic method of isothiocyanate liquid crystal monomers
-
Paragraph 0033-0040, (2021/01/30)
The invention discloses a synthetic method of isothiocyanate liquid crystal monomers. The synthetic method comprises the following steps: taking a halogenated aniline as a raw material, firstly preparing an active intermediate of an isothiocyanate group, reacting with different coupling substrates, and then purifying to obtain a series of isothiocyanate liquid crystal monomers. The method comprises the steps of salifying, isothiocyanic acid esterification, coupling and purification to finally obtain the product. According to the method, the reaction paths and post-treatment are optimized, andhigh yield is achieved while the product purity is guaranteed.
NOVEL BENZIMIDAZOLE BASED EGFR INHIBITORS
-
Page/Page column 12, (2016/06/15)
The present invention disclosed a novel EGFR inhibitor compound of formula (I), process for preparation thereof and methods of treating abnormal cell growth in mammals by administering the compounds of formula (I). Wherein, R= -H, 3-CH3, 4-NO2, 4-Cl, 2-CH3, 4-CH3, 4-Br, 4-F R1= -H, -4-OCH3, -4-NO2,-2-NO2, -4-Cl, -2,4,6-CH3, -4-CH3, -2-F,4-Br, -4-CF3, -4-S-CH3, -4-Cl,-3-CF3, -3-S-CH3, -3,5-CF3, -2-S-CH3, -3-CF3,-4-OCF3, -Si-(CH3)3, -Si-(C2H5)3, (CH3)2-Si- C2H5.
Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: Potent S1P1 agonists with in vivo lymphocyte-depleting activity
Frohn, Mike,Cee, Victor J.,Lanman, Brian A.,Pickrell, Alexander J.,Golden, Jennifer,Rivenzon-Segal, Dalia,Middleton, Scot,Fiorino, Mike,Xu, Han,Schrag, Michael,Xu, Yang,McElvain, Michele,Muller, Kristine,Siu, Jerry,Bürli, Roland
supporting information; experimental part, p. 628 - 633 (2012/03/11)
An SAR campaign designed to increase polarity in the 'tail' region of benzothiazole 1 resulted in two series of structurally novel 5-and 6-substituted S1P1 agonists. Structural optimization for potency ultimately delivered carboxamide (+)-11f,